The US company will issue iPhones to participants of the trial to analyse the effect of bacteria on acne
AOBiome, a US company that focuses on the development of probiotic skin care products, has announced the launch of a new trial that will use smartphones to collect real-time patient data.
The trial is being conducted with clinical research company Science 37 and will test how live bacteria can be used to treat adult acne. Approximately 372 patients are enrolled for the treatment, which is due to be completed by the third quarter of 2017.
Following AOBiome’s Phase 1B/2A study, the Phase 2B trial is said to be the first study to use smartphones for data collection purposes. Patients are being enrolled across nine US states and will be sent medications and iPhones personally.
Todd Krueger, President of AOBiome, said: “Through this partnership, AOBiome is able to engage with a significantly wider and more diverse population faster, and more cost-effectively, than traditional methods.”